Related Experiment Video
Updated: Apr 1, 2026
Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients
Published on: September 20, 2020
Radiofrequency ablation plus chemoembolization versus radiofrequency ablation alone for hepatocellular carcinoma: A
Qi-Wen Chen1, Hai-Feng Ying2, Song Gao3
1Fudan University Shanghai, Cancer Center, Department of Integrated Oncology, 200032 Shanghai, PR China; Fudan University, Institute of Clinical Epidemiology, School of Public Health, Key Laboratory of Public Health Safety of Ministry of Education, 200032 Shanghai, PR China.
Background:
To determine whether the use of radiofrequency ablation (RFA) plus transcatheter arterial chemoembolization (TACE) is more effective than the use of RFA alone for patients with hepatocellular carcinoma (HCC).
Methods:
A computer-based search was performed. Randomised trials comparing RFA plus TACE and RFA alone for treatment of HCC were included in this meta-analysis. The outcome of interest for our analysis was survival (recurrence-free survival and overall survival).
Results:
Eight trials with 648 patients were eligible for this meta-analysis. Our pooled results suggest that RFA plus TACE is associated with a significant advantage in recurrence-free survival (RFS) (HR=0.58; 95% CI=0.42-0.80, P=0.001), and overall survival (OS) (HR=0.60; 95% CI=0.47-0.76, P<0.001).
Conclusion:
TACE combined with RFA was more effective than RFA alone, especially for treatment for intermediate and large-size hepatic tumours or younger patients with HCC.
